Relationship between Non-Hodgkin’s lymphoma and blood levels of Epstein-Barr Virus in children in north-western Tanzania: a case control study

BMC Pediatrics

Damas Mwizamuholya²  Maria Raffaella Petrara⁵  Anita De Rossi⁵  Benson Kidenya⁴  Erasmus Kamugisha⁴  Peter Rambau³  Nestory Masalu¹  Rogatus Kabyemera² 

[1] Department of Oncology, Bugando Medical Centre, P.O. Box 1370, , Mwanza, Tanzania;Department of Pediatrics and Child Health, Bugando Medical Centre, P.O. Box 1370, , Mwanza, Tanzania;Department of Pathology, Catholic University of Health and Allied Sciences – Bugando, P.O. Box 1464, , Mwanza, Tanzania;Department of Biochemistry and Molecular Biology, Catholic University of Health and Allied Sciences – Bugando, P.O. Box 1464, , Mwanza, Tanzania;Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Unit of Viral Oncology, IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy

关键词: EBV;    HIV;    Children;    Non-Hodgkin’s Lymphoma;   

Others  :  1170580
DOI  :  10.1186/1471-2431-13-4

 received in 2012-07-12, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

Background

Non-Hodgkin’s Lymphomas (NHL) are common in African children, with endemic Burkitt’s lymphoma (BL) being the most common subtype. While the role of Epstein-Barr Virus (EBV) in endemic BL is known, no data are available about clinical presentations of NHL subtypes and their relationship to Human Immunodeficiency Virus (HIV) infection and Epstein Barr Virus (EBV) load in peripheral blood of children in north-western, Tanzania.

Methods

A matched case control study of NHL subtypes was performed in children under 15 years of age and their respective controls admitted to Bugando Medical Centre, Sengerema and Shirati district designated hospitals in north-western, Tanzania, between September 2010 and April 2011. Peripheral blood samples were collected on Whatman 903 filter papers and EBV DNA levels were estimated by multiplex real-time PCR. Clinical and laboratory data were collected using a structured data collection tool and analysed using chi-square, Fisher and Wilcoxon rank sum tests where appropriate. The association between NHL and detection of EBV in peripheral blood was assessed using conditional logistic regression model and presented as odds ratios (OR) and 95% confidence intervals (CI).

Results

A total of 35 NHL cases and 70 controls matched for age and sex were enrolled. Of NHLs, 32 had BL with equal distribution between jaw and abdominal tumour, 2 had large B cell lymphoma (DLBCL) and 1 had NHL-not otherwise specified (NHL-NOS). Central nervous system (CNS) presentation occurred only in 1 BL patient; 19 NHLs had stage I and II of disease. Only 1 NHL was found to be HIV-seropositive. Twenty-one of 35 (60%) NHL and 21 of 70 (30%) controls had detectable EBV in peripheral blood (OR = 4.77, 95% CI 1.71 – 13.33, p = 0.003). In addition, levels of EBV in blood were significantly higher in NHL cases than in controls (p = 0.024).

Conclusions

BL is the most common childhood NHL subtype in north-western Tanzania. NHLs are not associated with HIV infection, but are strongly associated with EBV load in peripheral blood. The findings suggest that high levels of EBV in blood might have diagnostic and prognostic relevance in African children.

【 授权许可】

   
2013 Kabyemera et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]The JES: WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2008, 2009:523-531.
• [2]Sandlund JT, Downing JR, Crist WM: Non-Hodgkin’s lymphoma in childhood. N Engl J Med 1996, 334:1238-1248.
• [3]Young JL Jr, Ries LG, Silverberg E, Horm JW, Miller RW: Cancer incidence, survival, and mortality for children younger than 15 years. Cancer 1986, 58:598-602.
• [4]Nunnari G, Smith JA, Daniel R: HIV 1 Tat and AIDS-associated cancer: targeting the cellular anti-cancer barrier? J Exp Clin Cancer Res 2008, 27:3. BioMed Central Full Text
• [5]Mutalima N, Molyneux E, Jaffe H, Kazima S, Borgstein E, Mkandawine N, Liomba G, Batumba M, Lagos D, Gratix F, Boshoff C, Casabonne D, Carpenter LM, Newton R: Associations between Burkitt’s lymphoma among children in Malawi and infection with HIV, EBV and Malaria: Results from a case–control study. PLoS One 2008, 3:e2005.
• [6]Filipovich AH, Mathur A, Kamat D, Shapiro RS: Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992, 52(Suppl):5465s-5467s.
• [7]Goldsby RE, Carroll WL: The molecular biology of pediatric lymphomas. J Pediatr Hematol Oncol 1998, 20:282-296.
• [8]Aka P, Kawira E, Masalu N, Emmanuel B, Brubaker G, Magatti J, Mbulaiteye SM: Incidence and trends in Burkitt lymphoma in northern Tanzania from 2000 to 2009. Pediatr Blood Cancer 2012, 59:1234-1238.
• [9]Murphy SB, Fairclough DL, Hutchison RE, Berard CW: Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989, 7:186-193.
• [10]Diebold J: Burkitt’s Lymphoma. In Pathology and genetics of tumours of haemopoietic and lymphoid Tissues. Edited by Jaffe E, Harris N, Stein H. Washington, DC: IARC Press; 2001:181-184.
• [11]Hassan R, Klumb CE, Felisbino FE, Guiretti DM, White LR, Stefanoff CG, Banos MH, Seuánez HN, Zalcberg IR: Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt’s lymphoma in Southeastern Brazil: epidemiological insights from an intermediate risk region. Haematologica 2008, 93:780-783.
• [12]Mwanda OW, Rochford R, Moorman AM, Macneil A, Whalen C, Wilson ML: Burkitt’s lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 2004, (8 Suppl):S68-S77.
• [13]Shapira J, Peylan-Ramu N: Burkitt's lymphoma. Oral Oncol 1998, 34:15-23.
• [14]Ministry of Health and social welfare: Burkitt’s lymphoma national treatment guidelines. Tanzania: Ocean Road Cancer Institute; 2009. ISBN 978-9987-9259-1-9
• [15]Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM: Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008, 123:2658-2663.
• [16]Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS: Sporadic childhood Burkitt lymphoma incidence in the United States during 1992–2005. Pediatr Blood Cancer 2009, 53:366-370.
• [17]Araujo I, Foss H, Bittencourt A, Hummel M, Demel G, Mendonca N, Herbst H, Stein H: Expression of Epstein-Barr virus gene products in Burkitt’s lymphoma in Northeast Brazil. Blood 1996, 87:5279-5286.
• [18]Davi F, Delecluse H, Guiet P, Gabarre J, Fayon A, Gentilhomme O, Felman P, Bayle C, Berger F, Audouin J, Bryon PA, Diebold J, Raphaël M: Burkitt-like lymphoma in AIDS patients: Characterization within a series of 103 human immunodefiency virus-associated non-Hodgkin’s lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol 1998, 16:3788-3795.
• [19]Newton R, Ziegler J, Valerie B, Edward M, Lucy C, Henry W, Sam M, Paul A, Gillian R, Harold J: A case–control study of Human Immunodeficiency Virus infection and cancer in adults and children residing in Kampala. Uganda Int J Cancer 2001, 92:622-627.
• [20]Newton R, Grulich A, Beral V, Sindikubwabo B, Ngilimana PJ, Nganyira A, Parkin DM: Cancer and HIV infection in Rwanda. Lancet 1995, 345:1378-1379.
• [21]Parkin MD, Garcia-Giannoli H, Raphael M, Martin A, Katangole-Mbidde E, Wabinga H, Ziegler S: Non- Hodgkin’s Lymphoma in Uganda: a case control study. AIDS 2000, 14:2929-2936.
• [22]Mbidde EK, Banura C, Kazura J, et al.: NHL and HIV infection in Uganda. 5th International Conference in Africa on AIDS. 1990.
• [23]Lazzi S, Ferrari F, Nyongo A, Polummo N, de Milito A, Zazzi M, Leoncini L, Luzi P, Tosi P: HIV-associated malignant lymphomas in Kenya (Equatorial Africa). Hum Pathol 1998, 29:1285-1289.
• [24]Peh SC, Nadarajah VS, Tai YC, Kim LH, Abdullah WA: Pattern of Epstein-Barr virus association in childhood non-Hodgkin’s lymphoma: experience of university of Malaya medical center. Pathol Int 2004, 54:151-157.
• [25]Kim D, Ko Y, Suh Y, Koo H, Huh J, Lee W: Characteristics of Epstein-Barr virus associated childhood non-Hodgkin’s lymphoma in the Republic of Korea. Virchows Arch 2005, 447:593-596.
• [26]Chabay PA, De Matteo EN, Aversa L, Maglio S, Grinstein S, Preciado MV: Assessment of Epstein-Barr virus association with pediatric non-Hodgkin lymphoma in immunocompetent and in immunocompromised patients in Argentina. Arch Pathol Lab Med 2002, 126:331-335.
• [27]Klumb CE, Hassan R, De Oliveira DE, De Resende LM, Carrico MK, De Almeida Dobbin J, Pombo-De-Oliveira , Bacchi CE, Maia RC: Geographic variation in Epstein-Barr virus associated Burkitt’s lymphoma in children from Brazil. Int J Cancer 2004, 108:66-70.
• [28]Anwar N, Kingwa DW, Bloch AR, Mourad M, Raffeld M, Franklin J, Magreth I, el Balkainy N, Jaffe ES: The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt’s lymphoma from Egypt. Epidemiologic correlations. Cancer 1995, 76:1245-1252.
• [29]Boyle MJ, Sewell WA, Sculley TB, Apolloni A, Turner JJ, Swanson CE, Penny R, Cooper DA: Subtypes of Epstein-Barr virus in human immunodeficiency virus–associated non-Hodgkin’s lymphoma. Blood 1991, 78:3004-3011.
• [30]Cavdar AO, Yavuz G, Babacan E, Gozdasoglu S, Unal E, Ertem U, Parmir A, Yücesan S, Gokcora H, Uluoglu O, Ikinciogullari A: Burkitt’s lymphoma in Turkish children: clinical, viral [EBV] and molecular studies. Leuk Lymphoma 1994, 14:323-330.
• [31]Stevens SJ, Vervoort MB, Van der Brule AJ, Meenhorst P, Meijer CJ, Middledorp JM: Monitoring of Epstein - Barr virus DNA Load in Peripheral Blood by Quantitative Competitive PCR. J Clin Microbiol 1999, 37:2852-2857.
• [32]Kelsey , et al.: Methods in Observational Epidemiology 2nd Edition, Table 12–15 Fleiss, Statistical Methods for Rates and Proportions, formulas 3.18 &3.19. New York: Oxford University Press; 1996.
• [33]Murphy SB: Non-Hodgkin’s Lymphoma in Children. N Engl J Med 1978, 299:1446-1448.
• [34]National AIDS Control Programme: National Guidelines for the clinical management of HIV and AIDS. 2nd edition. 2005.
• [35]Abbate I, Zanchetta M, Gatti M, Gabrielli L, Zanussi S, Milia MG, Lazzarotto T, Tedeschi R, Ghisetti B, Clementi M, De Rossi A, Baldanti F, Capobianchi MR: Multicenter comparative study of Epstein-Barr virus DNA quantification for virological monitoring in transplanted patients. J Clin Virol 2011, 50:224-229.
• [36]Righetti E, Ballon G, Ometto L, Cattelan AM, Menin C, Zanchetta M, Chieco-Bianchi L, De Rossi A: Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS 2002, 16:63-73.
• [37]Burighel N, Ghezzi S, Nozza S, Del Bianco P, Lazzarin A, Tambussi G, Poli G, De Rossi A: Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy. Haematologica 2006, 91:244-247.
• [38]Petrara MR, Cattelan AM, Zanchetta M, Sasset L, Freguja R, Gianesin K, Cecchetto MG, Carmona F, De Rossi A: Epstein -Barr virus load and immune activation in Human Immunodeficiency Virus type 1-infected patients. J Clin Virol 2012, 53:195-200.